Inventor · disambiguated record
Mark Heipel
Also filed as: HEIPEL MARK · HEIPEL MARK D
4 granted patents·11 pending applications·49 citations·filing 1994–2018
71Inventor score
Top patents by PatentIndex Score
15 records- 0180US9663568B2Antibodies that bind peptidoglycan recognition protein 1NOVO NORDISK AS·Filed 2012·Granted May 30, 2017·4 cites·14 claims
- 0274US5641655AMethods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptideZYMOGENETICS INC·Filed 1994·Granted Jun 24, 1997·45 cites·26 claims
- 0364US2009269304A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2009·Application pending·0 cites
- 0463US2009087404A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2008·Application pending·0 cites
- 0557US2007122382A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2006·Application pending·0 cites
- 0657US2007048264A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2006·Application pending·0 cites
- 0757US2007178063A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2006·Application pending·0 cites
- 0856US10906965B2Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1NOVO NORDISK AS·Filed 2018·Granted Feb 2, 2021·0 cites·6 claims
- 0956US10150809B2Antibodies that bind peptidoglycan recognition protein 1NOVO NORDISK AS·Filed 2017·Granted Dec 11, 2018·0 cites·20 claims
- 1053US2011086004A1Methods of treating cancer using il-21 and monoclonal antibody therapyZYMOGENETICS INC·Filed 2010·Application pending·0 cites
- 1148US2005265966A1Methods of treating cancer using IL-21 and monoclonal antibody therapyKINDSVOGEL WAYNE R·Filed 2005·Application pending·0 cites
- 1245US2011300098A1Methods of treating cancer using il-21 and monoclonal antibody therapyKINDSVOGEL WAYNE R·Filed 2010·Application pending·0 cites
- 1344US2021198372A1Methods for dosing and for modulation of genetically engineered cellsJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1438US2024018268A1Anti-idiotypic antibodies against anti-cd19 antibodiesJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1538US2020078400A1Methods for determining car-t cells dosingJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →